- Home
- ANAB vs RCKT Comparison
ANAB vs RCKT Comparison
Compare ANAB & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- RCKT
- Stock Information
- Founded
- ANAB 2005
- RCKT 1999
- Country
- ANAB United States
- RCKT United States
- Employees
- ANAB N/A
- RCKT N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- ANAB Health Care
- RCKT Health Care
- Exchange
- ANAB Nasdaq
- RCKT Nasdaq
- Market Cap
- ANAB 759.5M
- RCKT 764.5M
- IPO Year
- ANAB 2017
- RCKT N/A
- Fundamental
- Price
- ANAB $19.59
- RCKT $6.99
- Analyst Decision
- ANAB Buy
- RCKT Strong Buy
- Analyst Count
- ANAB 10
- RCKT 10
- Target Price
- ANAB $37.75
- RCKT $43.90
- AVG Volume (30 Days)
- ANAB 589.1K
- RCKT 3.1M
- Earning Date
- ANAB 05-05-2025
- RCKT 05-08-2025
- Dividend Yield
- ANAB N/A
- RCKT N/A
- EPS Growth
- ANAB N/A
- RCKT N/A
- EPS
- ANAB N/A
- RCKT N/A
- Revenue
- ANAB $111,872,000.00
- RCKT N/A
- Revenue This Year
- ANAB N/A
- RCKT N/A
- Revenue Next Year
- ANAB $44.69
- RCKT N/A
- P/E Ratio
- ANAB N/A
- RCKT N/A
- Revenue Growth
- ANAB 387.20
- RCKT N/A
- 52 Week Low
- ANAB $12.21
- RCKT $4.55
- 52 Week High
- ANAB $41.31
- RCKT $26.98
- Technical
- Relative Strength Index (RSI)
- ANAB 48.98
- RCKT 48.90
- Support Level
- ANAB $18.51
- RCKT $6.21
- Resistance Level
- ANAB $21.52
- RCKT $8.26
- Average True Range (ATR)
- ANAB 1.16
- RCKT 0.54
- MACD
- ANAB -0.26
- RCKT 0.03
- Stochastic Oscillator
- ANAB 26.97
- RCKT 38.05
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.